희귀의약품 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)
Orphan Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1487541
리서치사:Transparency Market Research
발행일:2024년 04월
페이지 정보:영문 199 Pages
라이선스 & 가격 (부가세 별도)
한글목차
희귀의약품 시장 - 조사 범위
TMR의 희귀의약품 세계 시장 조사 보고서는 2024년부터 2034년까지 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측연도로 하여 2018년부터 2034년까지 세계 희귀의약품 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 희귀의약품 시장의 연평균 성장률(CAGR%)을 제시합니다.
이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참조하여 희귀의약품 시장을 이해했습니다.
시장 현황
2023년 시장 규모
1,950억 달러
2034년 시장 가치
4,240억 달러
CAGR
6.9%
이 보고서는 세계 희귀의약품 시장 경쟁 구도를 심층적으로 분석합니다. 세계 희귀의약품 시장에서 사업을 운영하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되어 있습니다. 기업 개요, 재무 상태, 최근 동향, SWOT는 이 보고서에서 다루는 세계 희귀의약품 시장 기업의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
서론
시장 개요
시장 역학
세계 시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 M&A
COVID-19 팬데믹의 산업에 대한 영향
제6장 세계 시장 분석과 예측 : 질환 유형별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 질환 유형별, 2020-2034년
종양
소화기
호흡기
신경
혈액
순환기
대사질환
내분비학
감염증
기타
시장의 매력 : 질환 유형별
제7장 세계 시장 분석과 예측 : 지표별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 지표별, 2020년-2034년
생물학적 제제
비생물학적 제제
시장의 매력 : 지표별
제8장 세계 시장 분석과 예측 : 유통 채널별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 유통 채널별, 2020년-2034년
병원 약국
전문 약국
소매 약국
기타
시장의 매력 : 유통 채널별
제9장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2020-2034
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 : 지역별
제10장 북미 시장 분석과 예측
제11장 유럽 시장 분석과 예측
제12장 아시아태평양 시장 분석과 예측
제13장 라틴아메리카 시장 분석과 전망
제14장 중동 및 아프리카 시장 분석과 전망
제15장 경쟁 구도
시장 경쟁 매트릭스(기업 Tier별·기업 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
Novartis AG
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi S.A.
Alexion Pharmaceuticals, Inc.
Eli Lilly and Company
Novo Nordisk A/S
AstraZeneca plc
Eisai Co., Ltd.
Daiichi Sankyo Company Limited
Bayer AG
GlaxoSmithKline plc
Merck & Co., Inc.
Johnson & Johnson
Biogen, Inc.
Shire plc
Amgen, Inc.
LSH
영문 목차
영문목차
Orphan Drugs Market - Scope of Report
TMR's report on the global orphan drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global orphan drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global orphan drugs market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the orphan drugs market.
Market Snapshot
Market Value in 2023
US$ 195 Bn
Market Value in 2034
US$ 424 Bn
CAGR
6.9%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global orphan drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global orphan drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global orphan drugs market.
The report delves into the competitive landscape of the global orphan drugs market. Key players operating in the global orphan drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global orphan drugs market profiled in this report.
Key Questions Answered in Global orphan drugs Market Report:
What is the sales/revenue generated by orphan drugs across all regions during the forecast period?
What are the opportunities in the global orphan drugs market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Orphan Drugs Market - Research Objectives and Research Approach
The comprehensive report on the global orphan drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global orphan drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global orphan drugs market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Orphan Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Orphan Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Orphan Drugs Market Analysis and Forecast, by Disease Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Type, 2020-2034
6.3.1. Oncology
6.3.2. Gastrointestinal
6.3.3. Pulmonary
6.3.4. Neurology
6.3.5. Hematology
6.3.6. Cardiovascular
6.3.7. Metabolic Disorders
6.3.8. Endocrinology
6.3.9. Infectious Diseases
6.3.10. Others
6.4. Market Attractiveness, by Disease Type
7. Global Orphan Drugs Market Analysis and Forecast, by Indicator
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indicator, 2020-2034
7.3.1. Biologic
7.3.2. Non-biologic
7.4. Market Attractiveness, by Indicator
8. Global Orphan Drugs Market Analysis and Forecast, By Distribution Channel
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Specialty Pharmacies
8.3.3. Retail Pharmacies
8.3.4. Others
8.4. Market Attractiveness, By Distribution Channel
9. Global Orphan Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Orphan Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Disease Type, 2020-2034
10.2.1. Oncology
10.2.2. Gastrointestinal
10.2.3. Pulmonary
10.2.4. Neurology
10.2.5. Hematology
10.2.6. Cardiovascular
10.2.7. Metabolic Disorders
10.2.8. Endocrinology
10.2.9. Infectious Diseases
10.2.10. Others
10.3. Market Attractiveness, by Disease Type
10.4. Market Value Forecast, by Indicator, 2020-2034
10.4.1. Biologic
10.4.2. Non-biologic
10.5. Market Attractiveness, by Indicator
10.6. Market Value Forecast, By Distribution Channel, 2020-2034
10.6.1. Hospital Pharmacies
10.6.2. Specialty Pharmacies
10.6.3. Retail Pharmacies
10.6.4. Others
10.7. Market Attractiveness, By Distribution Channel
10.8. Market Value Forecast, by Country/Sub-region, 2020-2034
10.8.1. U.S.
10.8.2. Canada
10.9. Market Attractiveness Analysis
10.9.1. By Disease Type
10.9.2. By Indicator
10.9.3. By Distribution Channel
10.9.4. By Country
11. Europe Orphan Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disease Type, 2020-2034
11.2.1. Oncology
11.2.2. Gastrointestinal
11.2.3. Pulmonary
11.2.4. Neurology
11.2.5. Hematology
11.2.6. Cardiovascular
11.2.7. Metabolic Disorders
11.2.8. Endocrinology
11.2.9. Infectious Diseases
11.2.10. Others
11.3. Market Attractiveness, by Disease Type
11.4. Market Value Forecast, by Indicator, 2020-2034
11.4.1. Biologic
11.4.2. Non-biologic
11.5. Market Attractiveness, by Indicator
11.6. Market Value Forecast, By Distribution Channel, 2020-2034
11.6.1. Hospital Pharmacies
11.6.2. Specialty Pharmacies
11.6.3. Retail Pharmacies
11.6.4. Others
11.7. Market Attractiveness, By Distribution Channel
11.8. Market Value Forecast, by Country/Sub-region, 2020-2034
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Market Attractiveness Analysis
11.9.1. By Disease Type
11.9.2. By Indicator
11.9.3. By Distribution Channel
11.9.4. By Country/Sub-region
12. Asia Pacific Orphan Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease Type, 2020-2034
12.2.1. Oncology
12.2.2. Gastrointestinal
12.2.3. Pulmonary
12.2.4. Neurology
12.2.5. Hematology
12.2.6. Cardiovascular
12.2.7. Metabolic Disorders
12.2.8. Endocrinology
12.2.9. Infectious Diseases
12.2.10. Others
12.3. Market Attractiveness, by Disease Type
12.4. Market Value Forecast, by Indicator, 2020-2034
12.4.1. Biologic
12.4.2. Non-biologic
12.5. Market Attractiveness, by Indicator
12.6. Market Value Forecast, By Distribution Channel, 2020-2034
12.6.1. Hospital Pharmacies
12.6.2. Specialty Pharmacies
12.6.3. Retail Pharmacies
12.6.4. Others
12.7. Market Attractiveness, By Distribution Channel
12.8. Market Value Forecast, by Country/Sub-region, 2020-2034
12.8.1. China
12.8.2. Japan
12.8.3. India
12.8.4. Australia & New Zealand
12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
12.9.1. By Disease Type
12.9.2. By Indicator
12.9.3. By Distribution Channel
12.9.4. By Country/Sub-region
13. Latin America Orphan Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease Type, 2020-2034
13.2.1. Oncology
13.2.2. Gastrointestinal
13.2.3. Pulmonary
13.2.4. Neurology
13.2.5. Hematology
13.2.6. Cardiovascular
13.2.7. Metabolic Disorders
13.2.8. Endocrinology
13.2.9. Infectious Diseases
13.2.10. Others
13.3. Market Attractiveness, by Disease Type
13.4. Market Value Forecast, by Indicator, 2020-2034
13.4.1. Biologic
13.4.2. Non-biologic
13.5. Market Attractiveness, by Indicator
13.6. Market Value Forecast, By Distribution Channel, 2020-2034
13.6.1. Hospital Pharmacies
13.6.2. Specialty Pharmacies
13.6.3. Retail Pharmacies
13.6.4. Others
13.7. Market Attractiveness, By Distribution Channel
13.8. Market Value Forecast, by Country/Sub-region, 2020-2034
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
13.9.1. By Disease Type
13.9.2. By Indicator
13.9.3. By Distribution Channel
13.9.4. By Country/Sub-region
14. Middle East & Africa Orphan Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease Type, 2020-2034
14.2.1. Oncology
14.2.2. Gastrointestinal
14.2.3. Pulmonary
14.2.4. Neurology
14.2.5. Hematology
14.2.6. Cardiovascular
14.2.7. Metabolic Disorders
14.2.8. Endocrinology
14.2.9. Infectious Diseases
14.2.10. Others
14.3. Market Attractiveness, by Disease Type
14.4. Market Value Forecast, by Indicator, 2020-2034
14.4.1. Biologic
14.4.2. Non-biologic
14.5. Market Attractiveness, by Indicator
14.6. Market Value Forecast, By Distribution Channel, 2020-2034
14.6.1. Hospital Pharmacies
14.6.2. Specialty Pharmacies
14.6.3. Retail Pharmacies
14.6.4. Others
14.7. Market Attractiveness, By Distribution Channel
14.8. Market Value Forecast, by Country/Sub-region, 2020-2034
14.8.1. GCC Countries
14.8.2. South Africa
14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
14.9.1. By Disease Type
14.9.2. By Indicator
14.9.3. By Distribution Channel
14.9.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Novartis AG
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Bristol-Myers Squibb Company
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Celgene Corporation
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. F. Hoffmann-La Roche Ltd.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Pfizer, Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Sanofi S.A.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Alexion Pharmaceuticals, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Eli Lilly and Company
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Novo Nordisk A/S
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. AstraZeneca plc
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Eisai Co., Ltd.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Daiichi Sankyo Company Limited
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. Bayer AG
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Product Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
15.3.14. GlaxoSmithKline plc
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Product Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.14.5. Strategic Overview
15.3.15. Merck & Co., Inc.
15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.15.2. Product Portfolio
15.3.15.3. Financial Overview
15.3.15.4. SWOT Analysis
15.3.15.5. Strategic Overview
15.3.16. Johnson & Johnson
15.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.16.2. Product Portfolio
15.3.16.3. Financial Overview
15.3.16.4. SWOT Analysis
15.3.16.5. Strategic Overview
15.3.17. Biogen, Inc.
15.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.17.2. Product Portfolio
15.3.17.3. Financial Overview
15.3.17.4. SWOT Analysis
15.3.17.5. Strategic Overview
15.3.18. Shire plc
15.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.18.2. Product Portfolio
15.3.18.3. Financial Overview
15.3.18.4. SWOT Analysis
15.3.18.5. Strategic Overview
15.3.19. Amgen, Inc.
15.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
